IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases
Nature Medicine2015Vol. 21(7), pp. 719–729
Citations Over TimeTop 1% of 2015 papers
Michele W.L. Teng, Edward P. Bowman, Joshua McElwee, Mark J. Smyth, Jean‐Laurent Casanova, Andrea M. Cooper, J. Daniel
Related Papers
- → Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab(2011)140 cited
- → Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study(2022)25 cited
- → Review of the safety and efficacy of ustekinumab(2010)43 cited
- → Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature.(2015)14 cited
- → Efficacy and safety of the interleukin-12/interleukin-23 antagonist ustekinumab in Korean patients with moderate to severe psoriasis(2016)